AI Echocardiography Patent Portfolio
Us2.ai holds eight issued United States patents on AI echocardiography, protecting the automated analysis workflow end to end: image recognition, cardiac measurement, acquisition guidance, and disease detection. Counterpart grants and approvals extend that protection internationally.
Issued United States Patents
Each patent below is issued by the United States Patent and Trademark Office (USPTO) and links to its public record. Patents are issued to Eko AI Pte Ltd, the Singapore-registered entity operating as Us2.ai.
Foundation: Automated Echo Analysis
The core patent family protecting fully automated recognition and analysis of echocardiogram images, without manual measurement.
Image Acquisition and Point of Care
Extending automated analysis upstream to the ultrasound device itself: image capture guidance and mobile point-of-care scanning.
Disease Detection and Severity Grading
Automated detection and grading of specific cardiac conditions from the same 2D and Doppler echo analysis pipeline.
Patent marking notice. This page is provided to satisfy the virtual patent marking provisions of 35 U.S.C. § 287(a). Us2.ai's automated echocardiography analysis software is protected by one or more of the United States patents listed above and by their international counterparts. Additional patent applications may be pending in the United States and other jurisdictions.
Protection Beyond the United States
The core patent family extends internationally through the Patent Cooperation Treaty application PCT/IB2018/001591, with counterpart patents granted or approved in five additional jurisdictions.
Common Patent Questions
For licensing, partnership, or IP questions not covered here, contact us.
Is Us2.ai's technology patented?
Yes. Us2.ai holds eight issued United States patents covering its automated AI echocardiography workflow, from image recognition and automated cardiac measurements to acquisition guidance and disease detection. Counterpart patents of the core family are granted in China, Japan, and Singapore and approved in Europe and Canada.
How many patents does Us2.ai hold?
Eight issued United States patents, plus international counterparts of the core patent family: granted in China (ZL 201880100205.3), Japan (JP 7290231 B2), and Singapore (11202105378Q), and approved in Europe and Canada.
Why do the patent records list Eko AI Pte Ltd as the assignee?
Eko AI Pte Ltd is the Singapore-registered legal entity that operates as Us2.ai. Public patent records at the USPTO and other patent offices carry the legal entity name, so patents assigned to Eko AI Pte Ltd are Us2.ai patents.
What do Us2.ai's patents cover?
The portfolio protects the automated clinical workflow end to end: AI recognition and analysis of 2D and Doppler modality echocardiogram images, automated cardiac measurements, federated learning for training the neural networks, diagnosis combining cardiac biomarkers with echo analysis, AI-based image capture guidance on ultrasound devices including mobile point-of-care scanners, and automated detection and severity grading of aortic stenosis, cardiac amyloidosis, and hypertrophic cardiomyopathy.
Are patents the same as regulatory clearance?
No. Patents protect the technology as intellectual property, while regulatory clearance (FDA 510(k), CE marking under EU MDR, MHRA registration) is what authorizes clinical use in a given market. Us2.ai holds both: eight issued US patents and clearance, registration or availability in 34 regulatory markets. See the Regulatory Status by Market page for clearances by country.
The science is peer-reviewed. The technology is patented.
See the Patented Workflow in Action
Eight issued United States patents protect the automation your lab would run on. Book a demo to see automated measurements, detection, and reporting on your own studies, or contact us about licensing and partnerships.